Guangdong Jiaying Pharmaceutical Co., Ltd (SHE:002198)
China · Delayed Price · Currency is CNY 3.820
-0.060 (-1.55%)
Sep 8, 2026, 3:04 PM CST
SHE:002198 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 350.39 | 383.5 | 375.41 | 533.03 | 659.03 | 574.28 |
Other Revenue | 0.17 | 0.25 | 0.76 | 0.2 | 0.17 | 0.44 |
| 350.56 | 383.75 | 376.17 | 533.23 | 659.2 | 574.71 | |
Revenue Growth | -11.23% | 2.02% | -29.45% | -19.11% | 14.70% | 5.50% |
Cost of Revenue | 160.67 | 157.64 | 152.13 | 186.34 | 229.22 | 143.26 |
Gross Profit | 189.89 | 226.12 | 224.04 | 346.9 | 429.98 | 431.45 |
Selling, General & Admin | 161.83 | 169.71 | 185.67 | 292.82 | 351.17 | 379.1 |
Research & Development | 10.33 | 9.04 | 6.76 | 10.1 | 15.34 | 14.4 |
Other Operating Expenses | 6.18 | 7.4 | 6.82 | 9.07 | 10.59 | 10.67 |
Operating Expenses | 176.48 | 185.62 | 203.29 | 311.34 | 379.76 | 402.16 |
Operating Income | 13.41 | 40.5 | 20.75 | 35.56 | 50.22 | 29.29 |
Interest Expense | -0.36 | -0.19 | -0 | -0 | -0.45 | -1.02 |
Interest & Investment Income | - | 0.57 | 2.08 | 2.7 | 2.74 | 3.67 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | - | - | - | - |
Other Non Operating Income (Expenses) | -5.45 | -0.27 | -0.02 | 0.01 | -0 | 1.48 |
EBT Excluding Unusual Items | 7.59 | 40.59 | 22.81 | 38.27 | 52.5 | 33.42 |
Gain (Loss) on Sale of Investments | -4.05 | -1.51 | - | 0.53 | 0.26 | -28.8 |
Gain (Loss) on Sale of Assets | -0.13 | -0.13 | 1.61 | 0.14 | -0.01 | -0.19 |
Asset Writedown | - | - | - | - | - | -0.01 |
Other Unusual Items | -1.05 | -1 | 0.68 | 0.44 | -1.65 | 1.39 |
Pretax Income | 2.36 | 37.95 | 25.1 | 39.37 | 51.1 | 5.82 |
Income Tax Expense | 4.94 | 7.47 | 4.48 | 5.05 | 7.16 | 4.35 |
Net Income | -2.58 | 30.48 | 20.61 | 34.32 | 43.93 | 1.48 |
Net Income to Common | -2.58 | 30.48 | 20.61 | 34.32 | 43.93 | 1.48 |
Net Income Growth | - | 47.87% | -39.94% | -21.88% | 2874.04% | -92.55% |
Shares Outstanding (Basic) | 506 | 507 | 508 | 508 | 507 | 509 |
Shares Outstanding (Diluted) | 506 | 507 | 508 | 508 | 507 | 509 |
Shares Change | -0.43% | -0.11% | -0.00% | 0.07% | -0.41% | 0.40% |
EPS (Basic) | -0.01 | 0.06 | 0.04 | 0.07 | 0.09 | 0.00 |
EPS (Diluted) | -0.01 | 0.06 | 0.04 | 0.07 | 0.09 | 0.00 |
EPS Growth | - | 48.03% | -39.94% | -21.94% | 2886.21% | -92.58% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -123.52 | -100.92 | 22.14 | 93.39 | 24.41 | 49.46 |
Free Cash Flow Per Share | -0.24 | -0.20 | 0.04 | 0.18 | 0.05 | 0.10 |
Dividend Per Share | - | - | - | 0.050 | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 54.17% | 58.92% | 59.56% | 65.05% | 65.23% | 75.07% |
Operating Margin | 3.82% | 10.55% | 5.51% | 6.67% | 7.62% | 5.10% |
Profit Margin | -0.74% | 7.94% | 5.48% | 6.44% | 6.67% | 0.26% |
Free Cash Flow Margin | -35.23% | -26.30% | 5.89% | 17.51% | 3.70% | 8.61% |
EBITDA | 31.07 | 61.68 | 40.37 | 59.77 | 76.11 | 57.69 |
EBITDA Margin | 8.86% | 16.07% | 10.73% | 11.21% | 11.55% | 10.04% |
D&A For EBITDA | 17.67 | 21.18 | 19.62 | 24.21 | 25.89 | 28.4 |
EBIT | 13.41 | 40.5 | 20.75 | 35.56 | 50.22 | 29.29 |
EBIT Margin | 3.82% | 10.55% | 5.51% | 6.67% | 7.62% | 5.10% |
Effective Tax Rate | 209.44% | 19.69% | 17.87% | 12.83% | 14.02% | 74.63% |
Revenue as Reported | 184.81 | 383.75 | 376.17 | 533.23 | 659.2 | 574.71 |
Advertising Expenses | - | 60.16 | 59.46 | 52.85 | 63.8 | 59.47 |